Prognostic values of S100 family members in ovarian cancer patients

Bai, Yang; Li, Liang-Dong; Li, Jun; Lu, Xin

doi:10.1186/s12885-018-5170-3

BMC Cancer

Table 1 Correlation of S100 with different pathological grade status of ovarian cancer patients

From: Prognostic values of S100 family members in ovarian cancer patients

S100 family	Affymetrix IDs	No. of patients (n)		Grade	HR	95%CI	P value
S100 family	Affymetrix IDs	low exp	high exp	Grade	HR	95%CI	P value
S100A1	205334_at	23	33	I	0.59	0.23–1.49	0.25
		223	101	II	0.91	0.66–1.25	0.54
		542	473	III	0.89	0.75–1.05	0.16
		8	12	IV	0.07	0.01–0.34	3.20E-05
S100A2	204268_at	39	17	I	0.14	0.02–1.04	0.025
		80	244	II	1.3	0.91–1.86	0.15
		584	431	III	1.27	1.07–1.5	0.0051
		5	15	IV	1.83	0.59–5.69	0.29
S100A3	206027_at	23	33	I	2.22	0.73–6.77	0.15
		166	158	II	1.26	0.93–1.71	0.13
		319	696	III	0.78	0.65–0.93	0.0056
		9	11	IV	0.36	0.12–1.04	0.049
S100A4	203186_s_at	41	15	I	0.63	0.21–1.93	0.41
		233	91	II	1.46	1.06–2.03	0.021
		441	574	III	1.09	0.92–1.29	0.3
		11	9	IV	0.21	0.06–0.66	0.0036
S100A5	207763_at	39	17	I	0.53	0.17–1.62	0.26
		155	169	II	1.32	0.98–1.79	0.071
		255	760	III	0.79	0.66–0.95	0.011
		12	8	IV	0.44	0.15–1.3	0.13
S100A6	217728_at	13	43	I	0.41	0.14–1.19	0.092
		227	97	II	1.4	1.02–1.93	0.038
		699	316	III	0.83	0.7–1	0.051
		10	10	IV	0.29	0.1–0.88	0.021
S100A7	205916_at	27	14	I	4.36	1.42–13.42	0.0051
		227	97	II	0.84	0.6–1.17	0.3
		564	451	III	0.9	0.76–1.06	0.2
		6	14	IV	0.47	0.17–1.31	0.14
S100A7A	232170_at	32	24	I	0.52	0.19–1.39	0.18
		72	90	II	1.39	0.9–2.17	0.14
		177	215	III	0.81	0.63–1.04	0.093
				IV
S100A8	202917_s_at	41	15	I	0.46	0.13–1.61	0.22
		90	234	II	0.77	0.56–1.06	0.11
		318	697	III	0.75	0.63–0.89	0.0012
		4	16	IV	0.55	0.17–1.73	0.3
S100A9	203535_at	37	19	I	1.66	0.62–4.48	0.31
		104	220	II	0.75	0.55–1.03	0.071
		427	588	III	0.85	0.72–1	0.052
		14	6	IV	2.18	0.74–6.39	0.15
S100A10	200872_at	23	33	I	0.56	0.21–1.48	0.24
		122	202	II	1.34	0.97–1.84	0.072
		735	280	III	1.38	1.15–1.65	0.00058
		12	8	IV	0.56	0.21–1.48	0.24
S100A11	200660_at	14	42	I	0.62	0.24–1.62	0.32
		232	92	II	0.75	0.53–1.06	0.099
		591	424	III	1.1	0.93–1.3	0.26
		5	15	IV	1.58	0.51–4.89	0.42
S100A12	205863_at	35	21	I	1.91	0.73–4.99	0.18
		80	244	II	0.56	0.41–0.78	0.00043
		584	431	III	0.9	0.76–1.06	0.21
		12	8	IV	1.66	0.63–4.4	0.3
S100A13	202598_at	35	21	I	1.6	0.59–4.33	0.35
		209	115	II	0.73	0.53–1.01	0.058
		274	741	III	0.87	0.72–1.04	0.12
		9	11	IV	0.04	0–0.34	6.00E-05
S100A14	218677_at	27	29	I	1.86	0.65–5.32	0.24
		139	185	II	0.78	0.58–1.06	0.11
		601	414	III	0.87	0.74–1.03	0.11
		6	14	IV	0.34	0.12–0.97	0.035
S100A16	227998_at	11	30	I	0.53	0.17–1.63	0.26
		40	122	II	1.75	1.02–3.01	0.04
		263	129	III	1.29	1–1.67	0.05
				IV
S100B	209686_at	39	17	I	2.05	0.76–5.5	0.15
		242	82	II	1.41	1.02–1.94	0.036
		313	702	III	0.83	0.7–0.99	0.037
		4	16	IV	0.46	0.14–1.47	0.18
S100G	207885_at	13	43	I	0.27	0.09–0.87	0.019
		91	233	II	0.77	0.55–1.08	0.13
		358	657	III	0.87	0.73–1.03	0.11
		6	14	IV	0.71	0.26–1.94	0.51
S100P	204351_at	13	43	I	0.65	0.25–1.72	0.38
		108	216	II	0.87	0.64–1.2	0.4
		408	607	III	1.25	1.06–1.48	0.0096
		14	6	IV	0.08	0.01–0.62	0.0023
S100Z	1554876_a_at	9	32	I	301,908,007.1	0-Inf	0.031
		107	55	II	0.6	0.37–0.96	0.032
		233	159	III	1.29	1–1.66	0.051
				IV

Notes: exp expression, OS overall survival, HR hazard ratio, CI confidence interval

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com